Literature DB >> 15377972

Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.

Carine Schweizer1, Martial Saugy, Matthias Kamber.   

Abstract

Beta-2 agonists are on the list of prohibited substances in sport. Salbutamol by inhalation is permitted to treat allergic asthma, and/or exercise-induced asthma or exercise-induced bronchoconstriction. If the level of salbutamol in urine exceeds 1000 ng/mL, the result is considered as a doping violation with an anabolic steroid. We report a case of a track and field athlete who tested well above this limit during a competition. He had a valid therapeutic use exemption for the use of salbutamol by inhalation and he claimed that he never used salbutamol orally. Further studies under controlled application by inhalation showed that this limit was exceeded. We propose that sanctioning bodies in sport should consider this possibility before taking into account a two-year ban for the use of an anabolic steroid.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377972     DOI: 10.1097/00042752-200409000-00018

Source DB:  PubMed          Journal:  Clin J Sport Med        ISSN: 1050-642X            Impact factor:   3.638


  5 in total

1.  Beta2-Agonist Doping Control and Optical Isomer Challenges.

Authors:  Glenn A Jacobson; J Paul Fawcett
Journal:  Sports Med       Date:  2016-12       Impact factor: 11.136

Review 2.  beta2-Agonists at the Olympic Games.

Authors:  Kenneth D Fitch
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 3.  The World Anti-Doping Code: can you have asthma and still be an elite athlete?

Authors:  Ken Fitch
Journal:  Breathe (Sheff)       Date:  2016-06

4.  Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.

Authors:  Perrine Courlet; Thierry Buclin; Jérôme Biollaz; Irene Mazzoni; Olivier Rabin; Monia Guidi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-22

5.  Current anti-doping policy: a critical appraisal.

Authors:  Bengt Kayser; Alexandre Mauron; Andy Miah
Journal:  BMC Med Ethics       Date:  2007-03-29       Impact factor: 2.652

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.